Interview with the Co-Founder, Chairman and CEO and the COO: DBV Technologies S.A. (NASDAQ:DBVT)

Healthcare >> CEO Interviews >> October 23, 2015

Dr. Pierre-Henri Benhamou is Co-Founder, Chairman and Chief Executive Officer of DBV Technologies S.A. Dr. Benhamou co-founded DBV Technologies in 2002, and has served as Chief Executive Officer from 2002 to the present and Chairman of the board of directors since the initial public offering on NYSE Euronext Paris in March 2012. With Professor Christophe Dupont and Bertrand Dupont, he described for the first time and patented the epicutaneous method of immunotherapy and explored with the scientific team the wide range of applications of the method. Dr. Benhamou is a physician, specializing in pediatric gastroenterology. He has held numerous clinical and academic positions. He received the Altran Foundation Prize for Innovation in 2003 for his work on the development of diagnostic patch tests. Dr. Benhamou has published numerous papers and originated key scientific collaborations for DBV Technologies, and has been instrumental in forming the scientific advisory board. Dr. Benhamou received an M.D. in medicine from Faculte de Medecine de Paris in 1984 and his specialization degree in pediatrics in 1987. The board of directors believes that Dr. Benhamou’s leadership, deep knowledge of the company and scientific experience will allow him to drive DBV to success. Profile

David Schilansky is Chief Operating Officer of DBV Technologies S.A. Mr. Schilansky has served as Chief Financial Officer since December 2011 and has been appointed as Chief Operating Officer in January 2015 to support the CEO in the implementation of DBV’s strategy. He supervises all financial work, human resources, general secretary, communication, investor relations as well as partnership and business development activities. He is a member of the executive committee. From 2006 to 2011, Mr. Schilansky held various important positions at the Ipsen Group, or Ipsen, including Interim Chief Financial Officer, Deputy Chief Financial Officer, member of Ipsen’s executive committee, and other positions in the administration and finance department, and participated in various external growth operations and the creation of Ipsen’s investor relations function. From 2003 to 2006, Mr. Schilansky spent three years at Thomson Inc. — now Technicolor S.A. — as co-head of investor relations. From 1999 to 2002, he spent three years at Warburg Dillon Read — now UBS Investment Bank — in the field of mergers and acquisitions. Mr. Schilansky received a master’s degree from Universite de Paris Dauphine and a master’s degree from Imperial College in London. Profile

TWST: Describe what the company is today and its core technologies.

Dr. Benhamou: DBV is developing treatment for severe allergies that is an immunotherapy, but

Join for free to read a longer excerpt or purchase this article

Interview with the Co-Founder, Chairman and CEO and the COO: DBV Technologies S.A. (NASDAQ:DBVT)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the Co-Founder, Chairman and CEO and the COO: DBV Technologies S.A. (NASDAQ:DBVT)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS